The anti-LILRB1 antibody was found to significantly enhance ADCP when combined with CD20 and CD47 antibodies by analyzing different B-NHL cell lines and tumor cells from chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) patients. This evidence concerns the gene CD47 and neoplasm.